Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison
Open Access
- 1 September 2008
- journal article
- research article
- Published by Microbiology Society in Journal of General Virology
- Vol. 89 (9), 2204-2213
- https://doi.org/10.1099/vir.0.2008/000349-0
Abstract
Cross-neutralization between rabies virus (RABV) and two European bat lyssaviruses (EBLV-1 and -2) was analysed using lentiviral pseudotypes as antigen vectors. Glycoprotein (G-protein) cDNA from RABV challenge virus standard-11 (CVS-11) and EBLV-1 and -2 were cloned and co-expressed with human immunodeficiency virus (HIV) or murine leukemia virus (MLV) gag–pol and packageable green fluorescent protein (GFP) or luciferase reporter genes in human cells. The harvested lentiviral (HIV) vector infected over 40 % of baby hamster kidney (BHK) target cells, providing high-titre pseudotype stocks. Tests on blinded antibody-positive (n=15) and -negative (n=45) sera, predetermined by the fluorescent antibody virus neutralization (FAVN) test approved by the World Health Organization (WHO) and Office International des Epizooties (OIE), revealed that the CVS-11 pseudotype assay had 100 % concordance with FAVN and strongly correlated with neutralization titres (r 2=0.89). Cross-neutralization tests using sera from RABV-vaccinated humans and animals on pseudotypes with CVS-11, EBLV-1 and EBLV-2 envelopes showed that the relative neutralization titres correlated broadly with the degree of G-protein diversity. Pseudotypes have three major advantages over live-virus neutralization tests: (i) they can be handled in low-biohazard-level laboratories; (ii) the use of reporter genes such as GFP or β-galactosidase will allow the assay to be undertaken at low cost in laboratories worldwide; (iii) each assay requires <10 μl serum. This robust microassay will improve our understanding of the protective humoral immunity that current rabies vaccines confer against emerging lyssaviruses, and will be applicable to surveillance studies, thus helping to control the spread of rabies.Keywords
This publication has 34 references indexed in Scilit:
- Rabies Encephalitis in Malaria-Endemic Area, Malawi, AfricaEmerging Infectious Diseases, 2007
- The control of viral infection by tripartite motif proteins and cyclophilin ARetrovirology, 2007
- Efficacy of rabies biologics against new lyssaviruses from EurasiaVirus Research, 2005
- European bat lyssaviruses: an emerging zoonosisEpidemiology and Infection, 2003
- Production and Neurotropism of Lentivirus Vectors Pseudotyped with Lyssavirus Envelope GlycoproteinsMolecular Therapy, 2001
- Evidence of TwoLyssavirusPhylogroups with Distinct Pathogenicity and ImmunogenicityJournal of Virology, 2001
- Establishment of a New System for Determination of Coreceptor Usages of HIV Based on the Human Glioma NP-2 Cell LineBiochemical and Biophysical Research Communications, 1999
- In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral VectorScience, 1996
- Localization and immunological characterization of antigenic domains of the rabies virus internal N and NS proteinsVirus Research, 1987
- The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirusNature, 1984